{"organizations": [], "uuid": "659f2210588ec8473925e29f27d966183851a961", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180206.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-trovagene-completes-cycle-one-dosi/brief-trovagene-completes-cycle-one-dosing-in-first-patient-enrolled-in-phase-1b-2-clinical-trial-of-pcm-075-idUSASB0C47E", "country": "US", "domain_rank": 408, "title": "BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-06T21:21:00.000+02:00", "replies_count": 0, "uuid": "659f2210588ec8473925e29f27d966183851a961"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-trovagene-completes-cycle-one-dosi/brief-trovagene-completes-cycle-one-dosing-in-first-patient-enrolled-in-phase-1b-2-clinical-trial-of-pcm-075-idUSASB0C47E", "ord_in_thread": 0, "title": "BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075", "locations": [], "entities": {"persons": [{"name": "patie", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "trovagene inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 6 (Reuters) - Trovagene Inc:\n* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-06T21:21:00.000+02:00", "crawled": "2018-02-07T22:04:19.002+02:00", "highlightTitle": ""}